Weight-Loss Pill Approvals Push Retailers to Adapt to Shifting Consumer Demand

Consumer-facing companies are under increasing pressure to adapt to changing buying habits, as new research reveals that more than a third of Britons would prefer taking weight-loss pills over injections.

Following the UK approval of Eli Lilly’s new daily weight-loss pill, consumer transition toward oral medications is expected to gain speed, triggering broader shifts in retail spending.

A survey commissioned by audit, tax, and consulting firm RSM UK found that 34% of respondents would consider taking weight-loss medication in tablet form rather than via injection. Acceptance was highest among younger demographics, reaching 43% among Millennials and 42% among Gen Z.

The study, conducted by 3Gem between July 27 and July 31, revealed that higher earners were particularly inclined toward oral treatments. Over half (58%) of respondents earning an annual salary above £80,000 ($104,000) said they would consider taking weight-loss medication in pill form.

According to RSM, the growing adoption of GLP-1 receptor agonists represents a pivotal structural shift for consumer businesses, despite known side effects associated with the drug class.

Among survey participants, nearly a quarter (24%) reported past or current use of GLP-1 weight-loss injections. Of those users, 45% reported eating smaller meal portions, 39% snaked less frequently, and 32% reduced their alcohol consumption.

The widespread adoption of GLP-1 medications is already creating secondary demand across personal care categories. UK beauty retailer Lookfantastic reported rising demand for collagen supplements, hair loss treatments, and skin-firming products as consumers seek solutions for body volume changes.

"We’re already seeing signs of GLP-1s influencing consumer behavior," said Jacqui Baker, Head of Consumer Markets at RSM UK. "The question for consumer-facing businesses will be what happens to people’s baskets as they change what, when, and how much they consume."

Baker emphasized that the trend may trigger a reallocation of household spending rather than an overall spending reduction, highlighting clear opportunities in dietary supplements and health categories. Brands in the nutritional sector are already adapting to this shift; for example, health supplement brand AG1 expanded its product lineup with new formats to capture growing consumer focus on daily health routines.

"For retailers, the rise of weight-loss drugs could impact not just what they sell, but how they manage stock, sizing, and anticipate demand as consumers’ needs change," Baker added. "GLP-1s have the potential to become a catalyst for a much broader shift in consumer behavior."

Eli Lilly’s daily weight-loss pill, Foundayo, was authorized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The decision follows the MHRA's June approval of Novo Nordisk's oral tablet version of Wegovy.

Foundayo is currently awaiting evaluation by the National Institute for Health and Care Excellence (NICE), which determines cost-effectiveness for coverage under the UK's National Health Service (NHS).

Industry analysts forecast that oral GLP-1 tablets will carry significantly lower price points than injectable treatments, potentially accelerating consumer adoption across broader income brackets.